ArticleCureus2025
Clinical Outcomes of Vancomycin Powder for Surgical Site Prophylaxis in Orthopedic Surgeries: A Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical site infections (SSIs) remain a significant challenge in orthopedic surgery, despite existing methods for lowering SSI rates, contributing to increased morbidity, mortality, and healthcare costs. The search for more effective prophylaxis strategies is a major area of research to reduce postoperative morbidity and mortality. Topical application of vancomycin powder (VP) has been suggested as an adjunctive measure for reducing SSIs.
objectiveTo evaluate the effectiveness of intraoperative topical VP in preventing SSIs in orthopedic surgeries.
methodsA comparative hospital-based observational study was conducted at Future Hospital, Khartoum, from September 2021 to October 2022. A total of 300 patients undergoing orthopedic surgery were enrolled and divided into two equal groups: a VP group (n=150) receiving intra-wound VP and a control group (n=150) without VP. Data on postoperative SSI and other variables were collected from hospital records and analyzed using IBM SPSS Statistics for Windows, Version 26 (Released 2018; IBM Corp., Armonk, New York, United States).
resultsA total of 300 patients were included. The mean patient age was 42.4±19.5 years, and 205 patients (68.3%) were male. There were no significant differences between observed cases and control groups in age, gender, occupation, diagnosis, and type of operations. Fractures were the most common indication for surgery (158 patients, 52.7%), and decompression with fixation was the most frequent procedure (143 patients, 47.7%). Patient age was significantly associated with SSIs (p=0.009), with older patients showing higher rates. The SSI rate was significantly lower in the topical VP group (four patients, 2.7%) compared to the control group (11 patients, 7.3%) (P=0.042). No vancomycin-related adverse reactions were observed.
conclusionThe intraoperative application of VP significantly reduced the incidence of SSIs in orthopedic surgeries. Routine use of VP should be considered, especially in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.